Cancer immunotherapy company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Friedrich Graf Finckenstein as CMO. He was global head of oncology translational medicine of the Pharma Research and Early Development (pRED) unit of Roche (SIX:ROG; OTCQX:RHHBY). ViiV...

By acquiring ZymoGenetics Inc. for $885 million in cash, Bristol-Myers Squibb Co. will get full ownership of PEG-Interferon lambda in a bet that interferons will remain an essential part of HCV treatment for years to...

Having refocused its R&D exclusively on immunology as part of a cost-cutting effort, ZymoGenetics Inc. hopes to unlock some downstream value by out-licensing rights to a collection of shelved programs to Seattle Life Sciences Inc....

Although many compounds are shelved for good reasons, Avera Pharmaceuticals Inc. maintains that tapping the cupboard at pharma companies does not mean it will end up with second-rate opportunities. The company expects that the neurological...